Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- ADBE +4.9%, CPRT +4.1%, FDX +3.8%, NUS +1.9%, ( reaches resolution with the SEC, which fully resolves the previously disclosed SEC investigation in its entirety; sees Q3 revs at high end or above prior guidance), GTN+0.6%, DEO +0.5%, (issues trading update ahead of its AGM)
M&A news:
- ABB +0.7% (to sell its Cable Business to NKT Cables for EUR836 mln)
- SPWR +0.5% (8point3 Energy Partners LP to acquire Sunpower's 49% stake in its 102-MW Henrietta Solar Project for about $134 mln)
Select financial related names showing strength: BCS +3.9%, ING +3.7%, SAN +2.5%, CS +2.1%
Select metals/mining stocks trading higher: AU +4.6%, DRD +4.6%, VALE +3.7%, AG +3.5%, GFI +2.9%, GDX+2.5%, ABX +2.3%
Select oil/gas related names showing strength: CHK +3.4%, OAS +2.5%, MRO +2.4%, SSL +2.2%, RIG +1.9%,RDS.A +1.3%, BP +1.2%
Other news:
Select metals/mining stocks trading higher: AU +4.6%, DRD +4.6%, VALE +3.7%, AG +3.5%, GFI +2.9%, GDX+2.5%, ABX +2.3%
Select oil/gas related names showing strength: CHK +3.4%, OAS +2.5%, MRO +2.4%, SSL +2.2%, RIG +1.9%,RDS.A +1.3%, BP +1.2%
Other news:
- EBIO +12.8% (announces deal to acquire privately-held Viventia )
- USEG +10.1% (thinly traded, entered into an Earnings & Participation Agreement on a previously announced project with IronHorse Resources)
- ADMS +9.7% (announces results of EASE LID 3, says the improvement in LID was statistically significant and confirmed safety and efficacy data from earlier pivotal trials),
- CLVS +9.1% (continued strength following today's M&A chatter)
- SPSC +4.9% (to join S&P SmallCap 600)
- FOXF +4.9% (light volume - to join S&P SmallCap 600)
- FATE +4.7% (granted orphan designation by the FDA for ProTmune )
- EXEL +4.3% (will provide update on CABOzantinib in clinical data oral presentation at the ESMO Congress on Oct 10)
- SRPT +3.2% (announces favorable USPTO decisions in Exon 51 and Exon 53 composition of matter patent interference cases against BioMarin Pharmaceutical)
- AGTC +2.4% (CFO disclosed purchase of 10000 shares, worth total of $87.5K )
- KITE +1.6% ( enters an exclusive, worldwide license with the NIH for intellectual property related to multiple T-cell receptor based product candidates for the treatment of tumors expressing mutated KRAS antigens)
- AXAS +1.3% (sells its Portilla field and associated surface acreage for net proceeds of approximately $13 million and its 12,178 acre surface ranch and ½ of the Company's minerals on the property for gross proceeds of $6.7 million)
- TGT +1.3% (announces new $5 billion share repurchase program)
- MSFT +1.1% (dividend increased 8 percent; $40 billion authorized for share repurchase)
- COO +1.1% (to join the S&P 500)
- UPS +1% (following FDX earnings)
Analyst comments:
- CONN +7.3% (upgraded to Buy from Hold at Stifel)
- ANFI +6.5% (initiated with a Buy at Jefferies)
- ESV +5.7% (upgraded to Buy from Neutral at Goldman )
- PBYI +4.1% (upgraded to Buy at Stifel)
- BCS +3.9% (upgraded to Buy from Hold at HSBC)
- SYRG +2.6% (initiated with a Outperform at Credit Suisse)
- NE +2.5% (upgraded to Neutral from Sell at Goldman)